



4950 Research Park Way  
Lawrence, KS 66047  
Tel: 785-838-3767  
Fax: 785-838-3747

## For Immediate Release

### Dr. James Bristol joins Deciphera Pharmaceuticals Board of Managers

Deciphera Pharmaceuticals LLC (Lawrence, Kansas) announces the appointment of Dr. James A. Bristol to its Board of Managers, effective August 1, 2007. Dr. Bristol joins the Deciphera Board after recently retiring from Pfizer, Inc., where he held the position of Senior Vice President, Worldwide Discovery Research from 2003-2007. Prior to this position, he was Vice President, Discovery Research, at the Pfizer Global Research & Development site in Ann Arbor, Michigan from 2000-2003. Dr. Bristol was also with the Parke-Davis Pharmaceutical Research Division of Warner-Lambert from 1980-2000, where he rose through leadership positions culminating as Vice President, Discovery Research. Dr. Bristol has also exhibited outstanding leadership in the pharmaceutical and medicinal chemistry community, exemplified by serving on the Gordon Research Conferences Board of Trustees (1998 – 2004), serving as Editor in Chief, *Annual Reports in Medicinal Chemistry*, Academic Press (1990 – 1998), Senior Editor, *Current Opinion in the Chemistry of Drug Discovery and Development*, (1998 – present), and serving leadership roles in the American Chemical Society Division of Medicinal Chemistry, including National Chairman of the division during 1995. Dr. Bristol has 46 publications in peer-reviewed journals and 30 granted U.S. patents. In recognition of his service to the pharma industry, Dr. Bristol received the American Chemical Society's Earle B. Barnes Award for Leadership in Chemical Research Management in 2004.

Commenting on the recent appointment, Daniel Flynn, President and Chief Executive Officer stated, "We are honored to have Dr. Bristol join our board and regard his joining as a testament to Deciphera's significant advancement of its technology and kinase inhibitor portfolio over the last three years. Dr. Bristol will be a significant resource as we strategically grow the company, enter clinical trials, and form alliances with key partners."

**About Deciphera Pharmaceuticals.** Deciphera Pharmaceuticals, LLC is a drug discovery and development company focused on the introduction of small molecule Switch Pocket Inhibitors (SPIs) of protein kinases into human clinical trials and the global pharmaceutical marketplace. Through the use of its proprietary Phylomechanics technology platform, kinases are studied and regulated with SPIs by a mechanism which targets their Switch Pocket regions. Switch Pockets are regions within protein kinases which control kinase shapes and activity-states. Deciphera has demonstrated that kinase activity can be modulated by SPIs in unique ways. Importantly, these Switch Pockets vary widely among kinases (unlike the ATP cofactor pocket, which is similar from one kinase to the next), enabling the design of SPIs with unprecedented selectivity profiles. There are over 500 protein kinases in the human genome, and many of these have been linked to human disease. SPIs offer a unique mechanism for controlling unregulated kinase activity linked to human diseases such as cancer, chronic inflammation, immunological disorders, cardiovascular disease, ocular disease, and metabolic disorders. Deciphera's two most advanced kinase programs are in preclinical development, both of which are expected to enter human trials in 2008: a bcr-Abl inhibitor which potently targets wild-type and mutant forms including the T315I mutant for the treatment of chronic myelogenous leukemia; and a B-Raf inhibitor which potently targets the oncogenic V600E mutant form for the treatment of melanomas, colon cancer and other cancers.

---